Jared Moskowitz has a problem he didn't see coming. A Miami Herald report this week details how a Mamdani-inspired democratic socialist flipped Florida union support away from Moskowitz ahead of a primary challenge, borrowing the insurgent energy that took down a sitting congressman in New York and pointing it south. On Bluesky, Moskowitz keeps showing up in the same sentence as 22 House Democrats who voted with Republicans to kill Rashida Tlaib's resolution restricting U.S. Assistance to Israeli military operations in Lebanon. The left is taking notes. While all that was developing, Moskowitz filed two trades on May 6: he sold Cencora and bought Gilead Sciences. Two healthcare names. One pivot. The public record just sits there, waiting to be read.
The Primary Heat
The Herald piece is not a friendly story. The frame is explicit: the Mamdani playbook, which unseated a veteran New York Democrat by organizing labor and the activist left, is being imported to Florida's 23rd. A challenger is already in the field, and the union endorsements that Moskowitz might have counted on are not arriving on schedule.
Bluesky has 22 posts in the last 24 hours connecting Moskowitz to the Lebanon vote. That's not a wildfire, but it's a brush fire, and it's burning in exactly the demographic a member needs for a Democratic primary. The congressman who gets tagged in those posts doesn't get to pick which posts his voters see first.
Moskowitz has cultivated a brand as one of the louder Democrats on oversight and foreign policy, which is on-committee for him: he sits on the House Committee on Foreign Affairs and its Oversight and Intelligence subcommittee. That brand is now getting tested by a challenger who wants to use the Lebanon vote as exhibit one.
The Two Trades
On May 6, 2026, Moskowitz disclosed two moves filed on the same day. He sold Cencora (COR) in the $1,001-$15,000 range. He bought Gilead Sciences (GILD) in the same range.
These are not the same kind of healthcare company. Cencora is a pharmaceutical distributor, one of the three firms that functionally control how drugs move from manufacturers to pharmacies and hospitals in the United States. Gilead is a biotech and pharmaceutical manufacturer, best known for HIV antivirals and its hepatitis C franchise, and more recently for oncology plays.
The Venn diagram of what each company does overlaps only loosely. Distributing drugs and developing them are different business models with different regulatory exposures, different legislative risks, and different upside cases. Someone made a judgment call about which side of that trade to be on right now.
Neither Cencora nor Gilead sits in Moskowitz's committee jurisdiction. He's Foreign Affairs and Judiciary, not Energy and Commerce or Ways and Means, which are the committees that actually write pharmaceutical legislation. There are no flagged vote-trade overlaps on the May 6 trades. These are just trades.
His Full Record: 33 of 59
Context matters here. Moskowitz has 59 scored trades in the Blind Trust database. Thirty-three came in positive on 30-day alpha versus the S&P 500. Twenty-six did not. Mean 30-day alpha across the full sample: 0.2 percent. It's coin-flip territory with a slight lean.
His worst three disclosed trades all landed on the same day. On March 23, 2026, he sold Tractor Supply Company (TSCO) in two tranches, $15,001-$50,000 and $1,001-$15,000, and sold Automatic Data Processing (ADP) in the $1,001-$15,000 range. All three logged a negative 30-day alpha: TSCO down 10.0 percent against the index, ADP down 11.6 percent. No committee overlap on any of them. Bad timing or bad luck, pick one.
The best trades in his record carry a different conversation. On March 31, 2026, he purchased Broadcom (AVGO) in the $1,001-$15,000 range. Thirty-day alpha: plus 21.7 percent. Broadcom is flagged for committee overlap with Technology. Moskowitz is not on a technology committee. The "Technology" overlap flag in the data is a sector tag, not a direct committee assignment, and his actual committees are Foreign Affairs and Judiciary. A 21.7-point beat is a 21.7-point beat. The interpretation of what produced it's yours.
He also bought American Express (AXP) on October 10, 2025, in two tranches totaling up to $65,000. Thirty-day alpha on both: plus 13.8 percent. That trade carries a "Financial Services" committee overlap flag in the dataset, though Moskowitz is not assigned to the House Financial Services Committee. Again: the receipts are public. Make of them what you make of them.
The Votes That Are Actually His Business
Moskowitz's recent floor votes include a few worth naming. On June 29, he voted Yea on the TRIA Program Reauthorization Act of 2026, which renews the federal terrorism risk insurance backstop. Insurance sector relevance: real. Committee relevance for Moskowitz: none. He's Foreign Affairs and Judiciary.
On June 11, he voted Nay on the FISA reauthorization bill, H.R. 9238, which failed. That one is actually in his lane: the House Committee on the Judiciary's Crime and Federal Government Surveillance subcommittee is exactly where FISA oversight lives. His Nay on a bill that then failed is the kind of vote his committee work is supposed to produce, whether you agree with the outcome or not.
On June 25, he voted Yea on the Financial Exploitation Prevention Act of 2025. The bill passed. Financial sector adjacent, but squarely in the Judiciary Committee's consumer-protection orbit. Both of those votes are within the scope of his committee assignments. The floor votes on veterans' benefits, housing, and the KIDS Act are just floor votes, the kind every member casts on bills written by other committees entirely.
The Bigger Picture on the Trades
The Cencora-to-Gilead rotation on May 6 sits in a healthcare sector that's under active legislative pressure in 2026. Drug pricing, pharmacy benefit manager reform, and distributor liability have all been live issues in the 119th Congress. Moskowitz doesn't sit on the committees writing those bills, which means the trade doesn't carry a direct oversight angle under Blind Trust's methodology.
What it does carry is a question any retail investor would ask: why sell the distributor and buy the manufacturer right now? Cencora's business model is sensitive to drug-pricing legislation that compresses distributor margins. Gilead's pipeline has different regulatory exposure. Someone made a bet on which business model survives the current legislative environment better.
Members are required to disclose. They are not required to divest, recuse, abstain, blush, or explain themselves.
The Situation, Summarized
Moskowitz is entering a primary cycle with labor bleeding away to a challenger who's running the Mamdani script. His foreign policy votes are generating Bluesky heat from the left flank he'll need in June. His disclosure record over 59 scored trades shows a 33-26 split against the index, which is essentially average, with a few notable outliers in both directions.
The two trades filed May 6 are small-dollar moves, each capped at $15,000 at the high end. They're not the centerpiece of his portfolio story. But they landed the same week his political situation got more complicated, and they represent a view on the healthcare sector from someone who votes on legislation that touches it, even if he doesn't write that legislation from committee.
His full disclosure record is on Blind Trust. The primary calendar is public. The votes are on the roll call. The trades are in the filings. The connection between all three is the question a reader gets to answer.